Omid Ghamarnejad
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Omid Ghamarnejad has a total of 81 co-authors. Here are the top co-authors by number of shared publications:
- Elias Khajeh
Department of General, Visceral, and Transplantation Surgery, Heidelberg University Hospital, 69120 Heidelberg, Germany
13 shared publications - Arianeb Mehrabi
Department of General, Visceral, and Transplantation Surgery, Heidelberg University Hospital, 69120 Heidelberg, Germany
10 shared publications - Mohammad Golriz
Department of General, Visceral, and Transplantation Surgery, University of Heidelberg, 69120 Heidelberg, Germany
7 shared publications - Ali Ramouz
Department of General, Visceral, and Transplantation Surgery, Heidelberg University Hospital, 69120 Heidelberg, Germany
6 shared publications - Gregor Alexander Stavrou
Department of General, Visceral and Thoracic Surgery, Surgical Oncology, Klinikum Saarbruecken, Saarbruecken, Germany
6 shared publications - Hamraz Javaheri
German Research Center for Artificial Intelligence (DFKI), Kaiserslautern, Germany
5 shared publications
Latest Publications
- Open Access
- 13 April 2026
- Published by Association for Computing Machinery (ACM)
- p. 1-24
Same Patient, Same Space, Divergent Needs: Revealing Gaps and Design Opportunities in Surgeon–Anesthesiologist Collaboration
- 13 April 2026
- Published by Association for Computing Machinery (ACM)
- p. 1-24
Open AccessSame Patient, Same Space, Divergent Needs: Revealing Gaps and Design Opportunities in Surgeon–Anesthesiologist Collaboration
- Open Access
- 15 August 2025
- Published by JMIR Publications Inc. in JMIR XR and Spatial Computing
- Vol. 2 (1) , e73574
Assessing the Feasibility of Using Apple Vision Pro While Performing Medical Precision Tasks: Controlled User Study
Background: The emergence of next-generation video-see-through head-mounted displays, such as the Apple Vision Pro (AVP), has generated considerable interest in the medical field. While preliminary studies highlight AVP’s potential, no controlled study has rigorously assessed its usability for precision-based medical tasks requiring fine motor control and real-world perception. Objective: This study aims to evaluate the feasibility of using AVP while performing real-world medical precision tasks. Methods: To assess AVP’s feasibility, we conducted a controlled user study with 20 health care professionals, who performed 3 different suturing techniques across 3 intervention conditions. Participants completed the same tasks using AVP, the Microsoft HoloLens 2 (MHL2), and a baseline (without a head-mounted display). A within-subject design was used, ensuring that each participant experienced all intervention groups. We used a mixed methods research approach, incorporating both quantitative metrics, including task completion time, suturing performance, system usability score, cognitive load, virtual reality sickness, and presence score, as well as qualitative insights gathered through interviews. Results: Participants took significantly longer to complete the entire task using AVP (570.0, SD 192.0 s) compared with MHL2 (456.0, SD 120.0 s; P<.001) and baseline (472.0, SD 143.0 s; P<.001). The analysis on participants’ average suture performance revealed no significant differences across interventions (P=.76). The total raw NASA Task Load Index score among participants was significantly higher for AVP (43.9, SD 15.9) compared with MHL2 (21.5, SD 13.8; P<.001) and baseline (19.1, SD 15.1; P<.001). The analysis of the presence questionnaire demonstrated a significantly higher presence score for MHL2 (115.0, SD 11.4) compared with AVP (93.7, SD 12.7; P<.001). The overall virtual reality sickness questionnaire score was significantly higher for AVP (66.9, SD 19.8) compared with MHL2 (41.1, SD 9.32; P<.001). Moreover, the calculated system usability score for MHL2 (72.7, SD 8.54) was significantly higher compared with AVP (50.3, SD 14.4; P<.001). Conclusions: In conclusion, AVP has potential for non–time-sensitive medical applications or those that emphasize digital elements over real-world interaction. Its current usability limitations, particularly increased cognitive load and prolonged task execution times, suggest that further optimizations are necessary before widespread clinical adoption is feasible.
- 15 August 2025
- Published by JMIR Publications Inc. in JMIR XR and Spatial Computing
- Vol. 2 (1) , e73574
Open AccessAssessing the Feasibility of Using Apple Vision Pro While Performing Medical Precision Tasks: Controlled User Study
Background: The emergence of next-generation video-see-through head-mounted displays, such as the Apple Vision Pro (AVP), has generated considerable interest in the medical field. While preliminary studies highlight AVP’s potential, no controlled study has rigorously assessed its usability for precision-based medical tasks requiring fine motor control and real-world perception. Objective: This study aims to evaluate the feasibility of using AVP while performing real-world medical precision tasks. Methods: To assess AVP’s feasibility, we conducted a controlled user study with 20 health care professionals, who performed 3 different suturing techniques across 3 intervention conditions. Participants completed the same tasks using AVP, the Microsoft HoloLens 2 (MHL2), and a baseline (without a head-mounted display). A within-subject design was used, ensuring that each participant experienced all intervention groups. We used a mixed methods research approach, incorporating both quantitative metrics, including task completion time, suturing performance, system usability score, cognitive load, virtual reality sickness, and presence score, as well as qualitative insights gathered through interviews. Results: Participants took significantly longer to complete the entire task using AVP (570.0, SD 192.0 s) compared with MHL2 (456.0, SD 120.0 s; P<.001) and baseline (472.0, SD 143.0 s; P<.001). The analysis on participants’ average suture performance revealed no significant differences across interventions (P=.76). The total raw NASA Task Load Index score among participants was significantly higher for AVP (43.9, SD 15.9) compared with MHL2 (21.5, SD 13.8; P<.001) and baseline (19.1, SD 15.1; P<.001). The analysis of the presence questionnaire demonstrated a significantly higher presence score for MHL2 (115.0, SD 11.4) compared with AVP (93.7, SD 12.7; P<.001). The overall virtual reality sickness questionnaire score was significantly higher for AVP (66.9, SD 19.8) compared with MHL2 (41.1, SD 9.32; P<.001). Moreover, the calculated system usability score for MHL2 (72.7, SD 8.54) was significantly higher compared with AVP (50.3, SD 14.4; P<.001). Conclusions: In conclusion, AVP has potential for non–time-sensitive medical applications or those that emphasize digital elements over real-world interaction. Its current usability limitations, particularly increased cognitive load and prolonged task execution times, suggest that further optimizations are necessary before widespread clinical adoption is feasible.
- Open Access
- 4 July 2025
- Published by Association for Computing Machinery (ACM)
- p. 3205-3220
LLMs Enable Context-Aware Augmented Reality in Surgical Navigation
- 4 July 2025
- Published by Association for Computing Machinery (ACM)
- p. 3205-3220
Open AccessLLMs Enable Context-Aware Augmented Reality in Surgical Navigation
- Open Access
- 25 April 2025
- Published by Association for Computing Machinery (ACM)
- p. 1-24
From Concept to Clinic: Multidisciplinary Design, Development, and Clinical Validation of Augmented Reality-Assisted Open Pancreatic Surgery
- 25 April 2025
- Published by Association for Computing Machinery (ACM)
- p. 1-24
Open AccessFrom Concept to Clinic: Multidisciplinary Design, Development, and Clinical Validation of Augmented Reality-Assisted Open Pancreatic Surgery
- Open Access
- 1 December 2024
- Published by AME Publishing Company in HepatoBiliary Surgery and Nutrition
- Vol. 13 (6) , 1027-1029
Transforming liver surgery: the shift from traditional resections to minimally invasive and parenchymal-sparing techniques
Transforming liver surgery: the shift from traditional resections to minimally invasive and parenchymal-sparing techniques
- 1 December 2024
- Published by AME Publishing Company in HepatoBiliary Surgery and Nutrition
- Vol. 13 (6) , 1027-1029
Open AccessTransforming liver surgery: the shift from traditional resections to minimally invasive and parenchymal-sparing techniques
Transforming liver surgery: the shift from traditional resections to minimally invasive and parenchymal-sparing techniques
- Open Access
- 5 October 2024
- Published by Association for Computing Machinery (ACM)
- p. 176-180
ARAS: LLM-Supported Augmented Reality Assistance System for Pancreatic Surgery
The integration of Augmented Reality (AR) technology into surgical procedures offers significant potential to enhance clinical outcomes. Despite numerous lab-proven prototypes, deploying these systems in actual clinical settings demands specialized design and rigorous clinical evaluation to meet the high standards of complex medical fields. Our research highlights the intricate requirements emerging from clinical environments, particularly operating theaters. To address these challenges, we introduce ARAS, an operational AR assistance system for open pancreatic surgery. Through a user-centric design methodology, ARAS was iteratively developed and refined, ensuring its practical applicability and effectiveness in real-world surgical settings during clinical trials. ARAS encompasses two different modes designed for preoperative and intraoperative sessions. Preoperative mode enables surgeons to visualize patient data and perform resection on the patient's 3D reconstructed vessels and tumors, helping surgeons during surgical planning. Intraoperative mode allows in-situ and precise visualization of these reconstructed 3D models during the surgical procedure and supports surgeons in decision-making. ARAS also includes a novel interaction design for surgical AR systems. It uses LLMs to enable context-aware, intuitive, and natural communication between surgeons and the AR system. This demo showcases the capabilities of ARAS, emphasizing its potential to transform surgical practices through advanced AR and LLM-supported interactions.
- 5 October 2024
- Published by Association for Computing Machinery (ACM)
- p. 176-180
Open AccessARAS: LLM-Supported Augmented Reality Assistance System for Pancreatic Surgery
The integration of Augmented Reality (AR) technology into surgical procedures offers significant potential to enhance clinical outcomes. Despite numerous lab-proven prototypes, deploying these systems in actual clinical settings demands specialized design and rigorous clinical evaluation to meet the high standards of complex medical fields. Our research highlights the intricate requirements emerging from clinical environments, particularly operating theaters. To address these challenges, we introduce ARAS, an operational AR assistance system for open pancreatic surgery. Through a user-centric design methodology, ARAS was iteratively developed and refined, ensuring its practical applicability and effectiveness in real-world surgical settings during clinical trials. ARAS encompasses two different modes designed for preoperative and intraoperative sessions. Preoperative mode enables surgeons to visualize patient data and perform resection on the patient's 3D reconstructed vessels and tumors, helping surgeons during surgical planning. Intraoperative mode allows in-situ and precise visualization of these reconstructed 3D models during the surgical procedure and supports surgeons in decision-making. ARAS also includes a novel interaction design for surgical AR systems. It uses LLMs to enable context-aware, intuitive, and natural communication between surgeons and the AR system. This demo showcases the capabilities of ARAS, emphasizing its potential to transform surgical practices through advanced AR and LLM-supported interactions.
- Open Access
Promising Results of Associating Liver Partition and Portal Vein Ligation for Staged Hepatectomy for Perihilar Cholangiocarcinoma in a Systematic Review and Single-Arm Meta-Analysis
Background: ALPPS popularity is increasing among surgeons worldwide and its indications are expanding to cure patients with primarily unresectable liver tumors. Few reports recommended limitations or even contraindications of ALPPS in perihilar cholangiocarcinoma (phCC). Here, we discuss the results of ALPPS in patients with phCC in a systematic review as well as a pooled data analysis. Methods: MEDLINE and Web of Science databases were systematically searched for relevant literature up to December 2023. All studies reporting ALPPS in the management of phCC were included. A single-arm meta-analysis of proportions was carried out to estimate the overall rate of outcomes. Results: After obtaining 207 articles from the primary search, data of 18 studies containing 112 phCC patients were included in our systematic review. Rates of major morbidity and mortality were calculated to be 43% and 22%, respectively. The meta-analysis revealed a PHLF rate of 23%. One-year disease-free survival was 65% and one-year overall survival was 69%. Conclusions: ALPPS provides a good chance of cure for patients with phCC in comparison to alternative treatment options, but at the expense of debatable morbidity and mortality. With refinement of the surgical technique and better perioperative patient management, the results of ALPPS in patients with phCC were improved.
Open AccessPromising Results of Associating Liver Partition and Portal Vein Ligation for Staged Hepatectomy for Perihilar Cholangiocarcinoma in a Systematic Review and Single-Arm Meta-Analysis
Background: ALPPS popularity is increasing among surgeons worldwide and its indications are expanding to cure patients with primarily unresectable liver tumors. Few reports recommended limitations or even contraindications of ALPPS in perihilar cholangiocarcinoma (phCC). Here, we discuss the results of ALPPS in patients with phCC in a systematic review as well as a pooled data analysis. Methods: MEDLINE and Web of Science databases were systematically searched for relevant literature up to December 2023. All studies reporting ALPPS in the management of phCC were included. A single-arm meta-analysis of proportions was carried out to estimate the overall rate of outcomes. Results: After obtaining 207 articles from the primary search, data of 18 studies containing 112 phCC patients were included in our systematic review. Rates of major morbidity and mortality were calculated to be 43% and 22%, respectively. The meta-analysis revealed a PHLF rate of 23%. One-year disease-free survival was 65% and one-year overall survival was 69%. Conclusions: ALPPS provides a good chance of cure for patients with phCC in comparison to alternative treatment options, but at the expense of debatable morbidity and mortality. With refinement of the surgical technique and better perioperative patient management, the results of ALPPS in patients with phCC were improved.
- Open Access
- 28 April 2023
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 12 (9) , 3177
Correction: Oweira et al. Kynurenine Is the Main Metabolite of Tryptophan Degradation by Tryptophan 2,3-Dioxygenase in HepaRG Tumor Cells. J. Clin. Med. 2022, 11, 4794
There was an error in the original publication
- 28 April 2023
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 12 (9) , 3177
Open AccessCorrection: Oweira et al. Kynurenine Is the Main Metabolite of Tryptophan Degradation by Tryptophan 2,3-Dioxygenase in HepaRG Tumor Cells. J. Clin. Med. 2022, 11, 4794
There was an error in the original publication
- Open Access
Declined Organs for Liver Transplantation: A Right Decision or a Missed Opportunity for Patients with Hepatocellular Carcinoma?
Background: Liver transplantation is the only promising treatment for end-stage liver disease and patients with hepatocellular carcinoma. However, too many organs are rejected for transplantation. Methods: We analyzed the factors involved in organ allocation in our transplant center and reviewed all livers that were declined for transplantation. Reasons for declining organs for transplantation were categorized as major extended donor criteria (maEDC), size mismatch and vascular problems, medical reasons and risk of disease transmission, and other reasons. The fate of the declined organs was analyzed. Results: 1086 declined organs were offered 1200 times. A total of 31% of the livers were declined because of maEDC, 35.5% because of size mismatch and vascular problems, 15.8% because of medical reasons and risk of disease transmission, and 20.7% because of other reasons. A total of 40% of the declined organs were allocated and transplanted. A total of 50% of the organs were completely discarded, and significantly more of these grafts had maEDC than grafts that were eventually allocated (37.5% vs. 17.7%, p < 0.001). Conclusion: Most organs were declined because of poor organ quality. Donor-recipient matching at time of allocation and organ preservation must be improved by allocating maEDC grafts using individualized algorithms that avoid high-risk donor-recipient combinations and unnecessary organ declination.
Open AccessDeclined Organs for Liver Transplantation: A Right Decision or a Missed Opportunity for Patients with Hepatocellular Carcinoma?
Background: Liver transplantation is the only promising treatment for end-stage liver disease and patients with hepatocellular carcinoma. However, too many organs are rejected for transplantation. Methods: We analyzed the factors involved in organ allocation in our transplant center and reviewed all livers that were declined for transplantation. Reasons for declining organs for transplantation were categorized as major extended donor criteria (maEDC), size mismatch and vascular problems, medical reasons and risk of disease transmission, and other reasons. The fate of the declined organs was analyzed. Results: 1086 declined organs were offered 1200 times. A total of 31% of the livers were declined because of maEDC, 35.5% because of size mismatch and vascular problems, 15.8% because of medical reasons and risk of disease transmission, and 20.7% because of other reasons. A total of 40% of the declined organs were allocated and transplanted. A total of 50% of the organs were completely discarded, and significantly more of these grafts had maEDC than grafts that were eventually allocated (37.5% vs. 17.7%, p < 0.001). Conclusion: Most organs were declined because of poor organ quality. Donor-recipient matching at time of allocation and organ preservation must be improved by allocating maEDC grafts using individualized algorithms that avoid high-risk donor-recipient combinations and unnecessary organ declination.
- Open Access
- 16 August 2022
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 11 (16) , 4794
Kynurenine Is the Main Metabolite of Tryptophan Degradation by Tryptophan 2,3-Dioxygenase in HepaRG Tumor Cells
There are two main enzymes that convert tryptophan (Trp) to kynurenine (Kyn): tryptophan-2,3-dioxygenase (TDO) and indoleamine 2,3-dioxygenase (IDO). Kyn accumulation can promote immunosuppression in certain cancers. In this study, we investigated Trp degradation to Kyn by IDO and TDO in primary human hepatocytes (PHH) and tumoral HepaRG cells. To quantify Trp-degradation and Kyn-accumulation, using reversed-phase high-pressure liquid chromatography, the levels of Trp and Kyn were determined in the culture media of PHH and HepaRG cells. The role of IDO in Trp metabolism was investigated by activating IDO with IFN-γ and inhibiting IDO with 1-methyl-tryptophan (1-DL-MT). The role of TDO was investigated using one of two TDO inhibitors: 680C91 or LM10. Real-time PCR was used to measure TDO and IDO expression. Trp was degraded in both PHH and HepaRG cells, but degradation was higher in PHH cells. However, Kyn accumulation was higher in the supernatants of HepaRG cells. Stimulating IDO with IFN-γ did not significantly affect Trp degradation and Kyn accumulation, even though it strongly upregulated IDO expression. Inhibiting IDO with 1-DL-MT also had no effect on Trp degradation. In contrast, inhibiting TDO with 680C91 or LM10 significantly reduced Trp degradation. The expression of TDO but not of IDO correlated positively with Kyn accumulation in the HepaRG cell culture media. Furthermore, TDO degraded L-Trp but not D-Trp in HepaRG cells. Kyn is the main metabolite of Trp degradation by TDO in HepaRG cells. The accumulation of Kyn in HepaRG cells could be a key mechanism for tumor immune resistance. Two TDO inhibitors, 680C91 and LM10, could be useful in immunotherapy for liver cancers.
- 16 August 2022
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 11 (16) , 4794
Open AccessKynurenine Is the Main Metabolite of Tryptophan Degradation by Tryptophan 2,3-Dioxygenase in HepaRG Tumor Cells
There are two main enzymes that convert tryptophan (Trp) to kynurenine (Kyn): tryptophan-2,3-dioxygenase (TDO) and indoleamine 2,3-dioxygenase (IDO). Kyn accumulation can promote immunosuppression in certain cancers. In this study, we investigated Trp degradation to Kyn by IDO and TDO in primary human hepatocytes (PHH) and tumoral HepaRG cells. To quantify Trp-degradation and Kyn-accumulation, using reversed-phase high-pressure liquid chromatography, the levels of Trp and Kyn were determined in the culture media of PHH and HepaRG cells. The role of IDO in Trp metabolism was investigated by activating IDO with IFN-γ and inhibiting IDO with 1-methyl-tryptophan (1-DL-MT). The role of TDO was investigated using one of two TDO inhibitors: 680C91 or LM10. Real-time PCR was used to measure TDO and IDO expression. Trp was degraded in both PHH and HepaRG cells, but degradation was higher in PHH cells. However, Kyn accumulation was higher in the supernatants of HepaRG cells. Stimulating IDO with IFN-γ did not significantly affect Trp degradation and Kyn accumulation, even though it strongly upregulated IDO expression. Inhibiting IDO with 1-DL-MT also had no effect on Trp degradation. In contrast, inhibiting TDO with 680C91 or LM10 significantly reduced Trp degradation. The expression of TDO but not of IDO correlated positively with Kyn accumulation in the HepaRG cell culture media. Furthermore, TDO degraded L-Trp but not D-Trp in HepaRG cells. Kyn is the main metabolite of Trp degradation by TDO in HepaRG cells. The accumulation of Kyn in HepaRG cells could be a key mechanism for tumor immune resistance. Two TDO inhibitors, 680C91 and LM10, could be useful in immunotherapy for liver cancers.